Bleeding during rhinoplasty. 00
Conditions
Interventions
Intervention 1: Intervention group: Patients in the interventional group (first group) will be received an intravenous VENOFER- iron sucrose injection, 500 mg dissolved in Norma salin 0.9 % via pump i
Treatment - Drugs
Intervention group: Patients in the interventional group (first group) will be received an intravenous VENOFER- iron sucrose injection, 500 mg dissolved in Norma salin 0.9 % via pump infusion bolus fo
Control group: Patients in the the second group will received " placebo" as same bolus volume dissolved in Norma salin 0.9 % in a 30-minute intravenous infusion.
Sponsors
Vice chancellor for research, Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Male or female patients more than 18 years of age; no history of drug use; and willingness to cooperate in this study are enrolled. Exclusion criteria: patients with known allergy to the study drug; history of thromboembolic episodes; iron overload; hematologic diseases; hepatic and renal dysfunction; preoperative autologous blood donation and lack of signed informed consent will be excluded.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hemoglobin concentration. Timepoint: Pre operatio and post operation. Method of measurement: Questionnaire Lab. (g/dL). | — |
Secondary
| Measure | Time frame |
|---|---|
| Transfused blood products. Timepoint: perioperatively. Method of measurement: number of units.;Hemoglobin. Timepoint: Post operative. Method of measurement: g/dL.;Blood Pressure. Timepoint: During administration. Method of measurement: Blood pressure monitoring. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSaeed Tavanafar
Shiraz School of Dentistry
Outcome results
None listed